Trial Profile
Safety and Efficacy Study of Conbercept in Diabetic Macular Edema (DME) (Sailing)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 10 Oct 2022
Price :
$35
*
At a glance
- Drugs Conbercept (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Acronyms Sailing
- Sponsors Chengdu Kanghong Biological Science & Technology; Chengdu Kanghong Biotech
- 01 Oct 2022 2 years Results assessing efficacy and safety of intravitreal injections of conbercept versus laser photocoagulation ,published in the British Journal of Ophthalmology
- 08 Jun 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
- 22 Jul 2014 New trial record